Cordis CE marks stent for use in diabetics
This article was originally published in Clinica
Executive Summary
Warren, New Jersey-based Johnson & Johnson subsidiary Cordis has CE marked its Cypher Select Plus stent for sale in Europe for the treatment of diabetic patients. The expanded indication for Cypher Select Plus allows its use to treat coronary disease in patients with diabetes, who often present with challenging coronary anatomy. The stent has also been CE marked for use in patients with de novo lesions, in-stent restenosis, small vessels, chronic total occlusion, multivessel disease, bifurcations or acute myocardial infarction. The sirolimus-eluting device's European approval for use in diabetics follows Boston Scientific's paclitaxel-coated Taxus Liberté stent, approved for the same indication in January 2008 (see Clinica No 1289, p 18).